Cargando…
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer’s disease (AD) pathology. Increased BACE1 levels and activity have been reported in the brain of patients...
Autores principales: | Timmers, Maarten, Barão, Soraia, Van Broeck, Bianca, Tesseur, Ina, Slemmon, John, De Waepenaert, Katja, Bogert, Jennifer, Shaw, Leslie M., Engelborghs, Sebastiaan, Moechars, Dieder, Mercken, Marc, Van Nueten, Luc, Tritsmans, Luc, de Strooper, Bart, Streffer, Johannes Rolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325057/ https://www.ncbi.nlm.nih.gov/pubmed/28157093 http://dx.doi.org/10.3233/JAD-160829 |
Ejemplares similares
-
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016) -
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
por: Novak, Gerald, et al.
Publicado: (2020) -
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
por: Timmers, Maarten, et al.
Publicado: (2018) -
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors
por: Van Broeck, Bianca, et al.
Publicado: (2016) -
BACE2 distribution in major brain cell types and identification of novel substrates
por: Voytyuk, Iryna, et al.
Publicado: (2018)